GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipella Pharmaceuticals Inc (NAS:LIPO) » Definitions » EV-to-Revenue

Lipella Pharmaceuticals (Lipella Pharmaceuticals) EV-to-Revenue : 6.64 (As of May. 24, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lipella Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Lipella Pharmaceuticals's enterprise value is $2.99 Mil. Lipella Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.45 Mil. Therefore, Lipella Pharmaceuticals's EV-to-Revenue for today is 6.64.

The historical rank and industry rank for Lipella Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

LIPO' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.2   Med: 34.23   Max: 392.58
Current: 6.64

During the past 4 years, the highest EV-to-Revenue of Lipella Pharmaceuticals was 392.58. The lowest was 3.20. And the median was 34.23.

LIPO's EV-to-Revenue is ranked better than
55.3% of 1038 companies
in the Biotechnology industry
Industry Median: 8.22 vs LIPO: 6.64

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-24), Lipella Pharmaceuticals's stock price is $0.6492. Lipella Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.07. Therefore, Lipella Pharmaceuticals's PS Ratio for today is 9.84.


Lipella Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Lipella Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipella Pharmaceuticals EV-to-Revenue Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
- - 72.20 6.70

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.16 50.57 35.07 6.70 6.30

Competitive Comparison of Lipella Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Lipella Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipella Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lipella Pharmaceuticals's EV-to-Revenue falls into.



Lipella Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Lipella Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2.989/0.45
=6.64

Lipella Pharmaceuticals's current Enterprise Value is $2.99 Mil.
Lipella Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipella Pharmaceuticals  (NAS:LIPO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Lipella Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.6492/0.066
=9.84

Lipella Pharmaceuticals's share price for today is $0.6492.
Lipella Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.07.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipella Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lipella Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipella Pharmaceuticals (Lipella Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's lead product candidates include LP-10 and LP-310.
Executives
Lori Birder director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Daniel R Cohen director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Byong Kim director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Jonathan H Kaufman director, 10 percent owner, officer: See Remarks C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Ryan Pruchnic director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Douglas Johnston officer: Chief Financial Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Michael B Chancellor director, 10 percent owner, officer: Chief Medical Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Naoki Yoshimura director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208